Please proceed with registration and ordering once you have received your approval letter and promotional code from GSC.
This release includes new features, enhancements, and updates across user management, medication matching, report filtering, and more.
March 4, 2026
LabGx Updates: Report & System Enhancements
We have introduced enhancements to User and License Management to provide greater flexibility and administrative control. When sharing a license invite, assign a Clinic Identifier, Clinic Type, and Clinic Instance, plus enable shared access immediately. While selecting the Clinic Identifier, the appropriate clinic instance must be selected from the dropdown, and clinic instances can be configured for affiliated laboratories too.
Administrators retain the ability to modify the Clinic Type, Clinic Instance, or shared access settings at any time after the license has been assigned. New user accounts auto-verify on sign-up for immediate access, skipping the manual approval.
How the shared account works
The shared access feature lets multiple users view reports under a common Clinic Type, while maintaining individual identifiers through Clinic Instance (typically the user’s NPI number).
The Clinic Type is used to create a shared group of users. The Clinic Instance (usually the NPI) uniquely identifies each user within that group and ties orders or cases to a specific healthcare provider (HCP).
When assigning a case, both the Clinic Type and Clinic Instance are used to ensure the report is directed to the correct provider. However, if multiple users share the same Clinic Type and have Shared Access enabled, they are able to view each other’s assigned cases and reports within that shared group.
Example:
This allows reports to be shared across multiple users within the same clinic group while maintaining individual provider identification and administrative control.
RXCUI medication matching in LabGx has been improved for enhanced accuracy, consistency, and reliability. The updated logic maps medications to RXCUI codes more precisely, reducing mismatches and improving standardization across the platform.
LabGx now includes a new filtering capability for flagged reports to streamline troubleshooting. You can filter reports by specific flagged reasons, such as Medication Mismatch – Flagged or Genetic Mismatch/Unreported – Flagged. This helps users managing high report volumes quickly identify, categorize, and resolve issues.
To use this filter:
A new Extended Raw Report provides more comprehensive genetic and medication insights. It includes Drug-Gene Interaction (DGI) messages, current medications, report medications, recommended medications with severity levels, and a detailed phenotype table with star alleles. Labs gain deeper clinical transparency and insights into report data.
This is available as an add-on option for laboratories interested in enabling it.
A new MRN (Medical Record Number) Field enhances patient tracking in reports. Labs can optionally include MRN when submitting patient data. If included, the MRN will appear in the report header, making it easier to link reports to patient records.
To enable this feature:
To review order specifications for including the MRN, click here
Patient profile settings with hyperlinks
A new Unknown Medication section has been added to the report to improve visibility of unmatched medications. This section lists current medications that could not be matched and therefore were not analyzed for Drug–Gene Interactions (DGI). Previously omitted, providers can now see if these medications are part of the patient’s current regimen, even if they are not analyzed. This enhancement provides a more complete view of the patient’s medication profile.
Note: These medications were excluded from analysis for drug-gene interactions, drug-drug interactions, and renal or hepatic considerations due to an unknown medication record. Common reasons include discontinued medications, alternative naming conventions, or data entry variations. The medication name is displayed as entered.
Announcing support for multiple panels in Lab Studio PGx Panel Mapping for flexible, client-specific deployment. This enhancement makes it easier for laboratories to update existing panels and create new ones with the same flexibility used to build Lab Studio templates.
By selecting a reporting template, you can now create, customize, and deploy new panels directly within the selected template workflow. SupportBot is available to guide Lab Directors through this step-by-step.
Post-mapping, download Allele Coverage, Ambiguity Report and GeneDrugList.
To use the new panel mapping, your order.JSON file must be configured to include the panel ID in the `panel` parameter.
Please contact GenXys regarding validation requirements for any newly deployed panel. Note: Only active Lab Directors are authorized to deploy mappings.
Laboratory Report table fields now use updated, clinically precise terminology. HGVS column has been renamed to Allele Definition, and HGVS Reference has been renamed to Allele Information Reference.
Genomic Location column has been enhanced to reflect laboratory-reported information. Laboratories can now specify which genomic reference was used when reporting results providing greater flexibility and more accurate representation of genomic data. Available options include GRCh38, GRCh37, hg19, and RefGeneSeq.
Expanded customization options within LabStudio is now available, giving laboratories greater control over how information is displayed in the Laboratory Report table. Select columns like RSID, Genomic Location, Allele Information, Allele Information Reference, Genotype Result to fit your workflow.
Buprenorphine drug-gene interaction content is now available for panels testing CYP3A4 rs2740574, based on ClinPGx (PharmGKB) Level 3 evidence. Learn more: https://www.clinpgx.org/combination/PA130,PA448685/summaryAnnotation
Updates to thiopurine guidance (azathioprine, mercaptopurine, thioguanine) aligned with CPIC’s February 2026 guideline update, along with associated TPMT and NUDT15 mapping updates where applicable. Overall dosing guidance remains consistent with prior recommendations, with a few minor updates. The update also provides clearer alignment of recommendations for malignant vs. non-malignant indications for each of the three thiopurines. Learn more: https://blog.clinpgx.org/cpic-guideline-for/